Analyst Research Report Snapshot


Glenmark Pharmaceuticals Ltd. | First Cut Analysis




IndiaNivesh Securities Pvt Ltd


29 Jan 2013





Companies referenced:


Available for Immediate Download

Glenmark Pharmaceuticals Ltd. Slightly above estimates, maintain positive view on the stock At CMP of Rs 504, the stock is trading at P/E multiple of 24.5x & 21.1x of FY13E & FY14E earnings estimates respectively. During the quarter, company’s performance was slightly above our estimates & positive surprises were from ROW market & domestic market in Specialty segment. We intend to come out with detailed analysis after attending con call scheduled for tomorrow (30th Jan 2013).

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.